Single-cell profiling of PBMCs reveals distinct immune signatures associated with methotrexate response in rheumatoid arthritis
Year: 2026
Type: article
Study design: Observational Study
Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune disease with complex pathogenesis and clinical heterogeneity. Methotrexate (MTX) is the cornerstone treatment for RA, yet 30–40% of patients exhibit an inadequate response. This study aims to systematically compare the differences in immune characteristics between treatment-naïve patients and those treated with MTX, as well as between MTX responders and non-responders to identify biomarkers of MTX response. We conducted single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from treatment-naïve (TN), treatment success (TS), and treatment failure (TF) RA patients. We focused on the impact of methotrexate treatment on the proportion of immune cells and explored the differences between the MTX response group and non-response group. The scRNA-seq data revealed that MTX can broadly attenuate lymphocyte proliferation and rebalanced proinflammatory T helper subsets. For MTX responders and non-responders, the TS group displayed enhanced type I interferon (IFN-I) signaling and elevated proportions of regulatory T cells (Tregs), whereas the TF group demonstrated activation of TNFα pathways and expansion of cytotoxic NK-CD56dim-CD16hi-IFNG, which could recruit classical monocytes. Our study unveils distinct immune mechanisms underlying MTX response and identifies FKBP5 as a potential prognostic biomarker for personalized RA therapy. Our research findings indicate that MTX plays a key role in rebalancing the proportion of immune cells, including reducing the proportion of proinflammatory Th1/Th17 cells, conventional dendritic cells (cDCs) and plasma cells and increasing the proportion of Th2 cells and Tregs. Additionally, we found that compared with the TS group, the TF group had a stronger TNFα response score in myeloid cells, whereas myeloid cells in the TS group exhibited a higher type I interferon (IFN-I) response score.
Source: Arthritis Research & Therapy
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Keywords: rheumatoid arthritis, methotrexate response, treatment response biomarkers, peripheral blood mononuclear cells, immune cell composition, type I interferon signaling, TNF signaling, regulatory T cells, natural killer cells, classical monocytes, Th1/Th17 cells, Th2 cells, myeloid dendritic cells, plasma cells, FKBP5, myeloid cells, personalized treatment
Open Access status: gold
Estimated APC paid: $3,690
Award: G1067963856
OpenAlex ID: W7234305671
